Paclitaxel is a cytotoxic antineoplastic medicine belonging to the taxane class. Its primary mechanism involves microtubules, structures that are essential for normal cell division. Paclitaxel stabilizes microtubules and interferes with their normal reorganization, disrupting tumor-cell division and potentially resulting in cell death.
Recommended for:
Research and clinical evidence:
Paclitaxel therapy requires monitoring of blood counts because bone marrow suppression, particularly neutropenia, is a clinically important toxicity associated with treatment.
Paclitaxel is used for the treatment of selected malignant tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer. The specific regimen depends on tumor type, disease stage, previous treatment, and the patient's overall clinical condition.
Paclitaxel acts on tumor-cell microtubules, stabilizing them and interfering with the processes required for mitosis. This disrupts cell division and inhibits the growth of susceptible tumor cells.
Paclitaxel is administered intravenously only after appropriate dilution and preparation of the infusion solution by a qualified healthcare professional. The dose and infusion duration are individually determined according to the disease and selected chemotherapy regimen. PACLIWEL prescribing information describes different infusion schedules, including prolonged and three-hour intravenous administration.
Premedication is generally administered before paclitaxel to reduce the risk of hypersensitivity reactions. Treatment requires regular blood-count monitoring, and subsequent courses should not be administered until adequate neutrophil and platelet recovery has occurred.
